- Proprietary
genetics program with strains high in CBG, CBD, CBN and other
high-potential cannabinoids
- Exclusive
rights to 1 million rare CBG seeds for the 2019 growing season and beyond
- Biomass
producing higher yields with up to 20% full-spectrum CBD and other
cannabinoids
- Multistate
farming presence in Oregon, California, Colorado and Kentucky projected to
cultivate 3,000 acres by 2020
- Sales
and distribution channels include contract wholesale, bulk wholesale,
in-house brands and white labeled products
- Disruptive
product formulation ensures water solubility, high bioavailability and
efficacy
- S.
hemp-derived CBD sales forecast calls for $22 billion by 2022
Hemptown
USA, headquartered in Central Point, Oregon, is a proven grower of
full-spectrum hemp biomass grown using premium seed genetics that contain less
than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%.
The company’s “soil to oil” methodology combines seasoned professionals working
in hand-picked agricultural microclimates located in Oregon’s famed Emerald
Triangle, Kentucky and Colorado.
Hemptown has exclusive rights to 1 million rare CBG
(cannabigerol) seeds genetically programmed to yield from 15% to 20%
full-spectrum non-intoxicating cannabinoids. As a result of a long-standing
relationship with the one of the world’s most respected cannabis breeding
companies – Oregon CBD Seeds – Hemptown is positioned to be a leading CBG
producer in the U.S. in 2019 and beyond.
In 2018 Hemptown’s harvest from its Oregon hemp farm was
150,000 pounds of full-spectrum biomass with CBD content hovering around 17%.
2018 harvest revenue expected to range from $8.1 million to $12.6 million. The
company is scaling up operations in 2019 to meet market demands and projects it
will reap over 1,000,000 pounds. By 2020, Hemptown projects potential revenues
in the $100 million to $200 million range are possible once additional farming
operations are at full strength.
Growth Strategy
By 2020, Hemptown anticipates it will have more than 3,000
acres in several states dedicated to hemp farming. Expansion plans include
increasing in-house extraction capabilities to boost profit margins by
providing additional CBD and CBG isolates and distillation services.
Development of business-to-business channels as well as new products and
formulations for the direct-to-consumer market, along with several strategic
acquisitions, are also key to Hemptown’s growth strategy.
Hemptown plans to expand distribution and growing operations
globally through strategic partnerships and development of contracts with
leading Fortune 500 brands in European markets. The company intends to grow its
IP portfolio by developing a proprietary water-soluble cannabinoid delivery
system. Not to be confused with water-compatibility, water-soluble cannabinoids
combine seamlessly with other liquids, have a superior shelf life, and deliver
dramatically increased efficacy to the consumer.
Branded Products
Hemptown’s first in-house branded product line combines the
inspiring strength found in the unbridled nature that surrounds the company’s
original hemp farm in the Siskiyou Klamath region of Oregon. Siskū is set to
redefine the cannabinoid packaged goods space with an elegant look, clean feel
and potent, reliable efficacy.
Custom product lines can also be created for any product
manufacturer as Hemptown brings GMP and ISO accredited processing facilities
online in 2019. Together with Oregon CBD Seeds and Hemptown’s product sciences
team, Hemptown will be able to create custom, proprietary full-spectrum CBD and
CBG oils and pure isolates.
Management Team
Company Chairman Rod Wolterman founded Hemptown’s Oregon
operations in 2016. He has extensive experience in the cannabis sector having
been active within the space since 1998. Wolterman has also acted as a private
equity investor in numerous medical marijuana dispensaries and cultivation
operations in southern California.
CEO John Cummings has over 20 years of experience in finance,
marketing, sales and project management. He led the compliance and special
projects efforts for Kings Garden, one of the largest vertically integrated
operators in California. Cummings also spent a year in Europe launching the
continent’s first GMP and ISO-accredited cultivation and manufacturing
facility.
Dr. Gordon Chiu is chief science officer for Hemptown USA.
He has more than 15 years of combined domestic and international experience in
biomedical, chemical, cosmetic, medical and technology industries. A graduate
of Rensselaer Polytechnic Institute with a master’s degree from Seton Hall
University, Chiu is leading Hemptown’s cannabinoid research team and is
responsible for filing IP patents, specifically in the areas of
water-solubility, bioavailability and peptide sequencing.
For more information, visit the company’s website at www.HemptownUSA.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment